Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AJ201
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Recipient : Avenue Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AJ201 is a novel first-in-class asset in development for the treatment of spinal and bulbar muscular atrophy. It was designed to modify SBMA through multiple mechanism including degradation of the abnormal androgen receptor protein and by stimulating the...
Brand Name : AJ201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 27, 2023
Lead Product(s) : AJ201
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Recipient : Avenue Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AJ201
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Avenue Therapeutics
Deal Size : $253.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement, avenue therapeutics will develop and commercialize AJ201, a first-in-class clinical asset for the treatment of kennedy's disease. AnnJi will retain the manufacturing right to provide clinical and commercial suppl...
Brand Name : AJ201
Molecule Type : Small molecule
Upfront Cash : $3.0 million
March 10, 2023
Lead Product(s) : AJ201
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Avenue Therapeutics
Deal Size : $253.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AJ201
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Avenue Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Avenue Therapeutics will Develop and Commercialize AJ201, a first-in-class clinical asset currently in a Phase 1b/2a study in the U.S. for the treatment of spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease.
Brand Name : AJ201
Molecule Type : Small molecule
Upfront Cash : $3.0 million
March 02, 2023
Lead Product(s) : AJ201
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Avenue Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?